Literature DB >> 24799843

Induction and maintenance therapy with vedolizumab, a novel biologic therapy for ulcerative colitis.

.   

Abstract

Entities:  

Year:  2014        PMID： 24799843      PMCID： PMC4008963     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  11 in total

1.  Anti-adhesion molecule therapy for inflammatory bowel disease.

Authors:  Subrata Ghosh; Remo Panaccione
Journal:  Therap Adv Gastroenterol       Date:  2010-07       Impact factor: 4.409

Review 2.  Molecular basis of leukocyte-endothelium interactions during the inflammatory response.

Authors:  Olga Barreiro; Francisco Sánchez-Madrid
Journal:  Rev Esp Cardiol       Date:  2009-05       Impact factor: 4.753

3.  Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee.

Authors:  Asher Kornbluth; David B Sachar
Journal:  Am J Gastroenterol       Date:  2010-01-12       Impact factor: 10.864

Review 4.  Current misunderstandings in the management of ulcerative colitis.

Authors:  Thomas Ochsenkühn; Geert D'Haens
Journal:  Gut       Date:  2011-04-19       Impact factor: 23.059

Review 5.  Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis.

Authors:  Alexander C Ford; William J Sandborn; Khurram J Khan; Stephen B Hanauer; Nicholas J Talley; Paul Moayyedi
Journal:  Am J Gastroenterol       Date:  2011-03-15       Impact factor: 10.864

Review 6.  Review article: loss of response to anti-TNF treatments in Crohn's disease.

Authors:  S Ben-Horin; Y Chowers
Journal:  Aliment Pharmacol Ther       Date:  2011-03-02       Impact factor: 8.171

Review 7.  Vedolizumab for the treatment of ulcerative colitis and Crohn's disease.

Authors:  Leon P McLean; Terez Shea-Donohue; Raymond K Cross
Journal:  Immunotherapy       Date:  2012-09       Impact factor: 4.196

8.  Vedolizumab as induction and maintenance therapy for ulcerative colitis.

Authors:  Brian G Feagan; Paul Rutgeerts; Bruce E Sands; Stephen Hanauer; Jean-Frédéric Colombel; William J Sandborn; Gert Van Assche; Jeffrey Axler; Hyo-Jong Kim; Silvio Danese; Irving Fox; Catherine Milch; Serap Sankoh; Tim Wyant; Jing Xu; Asit Parikh
Journal:  N Engl J Med       Date:  2013-08-22       Impact factor: 91.245

9.  The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases.

Authors:  Dulce Soler; Tobias Chapman; Li-Li Yang; Tim Wyant; Robert Egan; Eric R Fedyk
Journal:  J Pharmacol Exp Ther       Date:  2009-06-09       Impact factor: 4.030

10.  Structural specializations of α(4)β(7), an integrin that mediates rolling adhesion.

Authors:  Yamei Yu; Jianghai Zhu; Li-Zhi Mi; Thomas Walz; Hao Sun; JianFeng Chen; Timothy A Springer
Journal:  J Cell Biol       Date:  2012-01-09       Impact factor: 10.539
View more
  1 in total

Review 1.  Infliximab is superior to other biological agents for treatment of active ulcerative colitis: A meta-analysis.

Authors:  Wei-Qun Mei; Hui-Zhen Hu; Ying Liu; Zhi-Chen Li; Wei-Guo Wang
Journal:  World J Gastroenterol       Date:  2015-05-21       Impact factor: 5.742
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.